Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Амиодарон-индуцированная дисфункция щитовидной железы

Список литературы

  1. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007; 298(11):1312-22.
  2. Singh BN. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol. 2008 Oct;52(4):300-5.
  3. Chazov EI, Dedov II. Cardiac and endocrine aspects of amiodarone therapy in modern practice of heart arrhythmia disorders treatment. Doctors manual. Moscow, 2005. Russian. (Чазов Е.И., Дедов И.И. Кардиальные и эндокринные аспекты применения амиодарона в современной практике лечения нарушений ритмов сердца. Пособие для врачей. Москва, 2005).
  4. Bogazzi F, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab. 2010; 95:2529-2535
  5. Martino E, Bartalena ME, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev. 2001; 22:240-254.
  6. Ahmed S, Van Gelder IC, Wiesfeld ACP et al. Determinations and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011; 75:388-394.
  7. Beddows SA, Page SR, Taylor AH, et al Cytotoxic Effects of Amiodarone and Desethylamiodarone on Human Thyrocytes. Biochem Pharmacol. 1989;38:4397-403.
  8. Holt DW, Tucker GT, Jackson PR, Storey GC. Amiodarone pharmacokinetics. Am Heart J. 1983 Oct;106(4 Pt 2):840-7.
  9. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005; 118: 706-14.
  10. Fukuchi H, Nakashima M, Araki R, et al. Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis. J Clin Pharm Ther. 2009; 34: 329-36.
  11. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone induced thyrotoxicosis and hypothyroidism. Am J Med. 1991; 91:507-511.
  12. Yamato M, Wada K, Hayashi T et al. Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction. Clin Drug Investig. 2018;38(1): 39-48.
  13. Sviridenko NYu, Platonova NM, Molashenko NV et al. Endocrine aspects of amiodarone  therapy in clinical practice. (Follow-up and treatment  algorithm for patients with thyroid dysfunction). Russian Journal of Cardiology. 2012;(2):63-71. Russian. (Свириденко НЮ, Платонова НМ, Молашенко НВ  и др. Эндокринные аспекты применения амиодарона в клинической практике. (Алгоритм наблюдения и лечения функциональных расстройств щитовидной железы). Российский кардиологический журнал. 2021;2:63-71.
  14. Lambert MJ, Burger AG, Galeazzi RL, Engler D. Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 mono- deiodination indicative of hyperthyroidism? J Clin Endocrinol Metab. 1982;55:1058–1065.
  15. Mel’nichenko GA, Sviridenko NYu, Molashenko NV et al. Amiodarone-induced thyroid dysfunction: pathigenesis, diagnosis, treatment. Review. Terapevticheskiy arkhiv. 2003;75 (8):92-6. Russian. (Мельниченко ГА, Свириденко НЮ, Молашенко НВ и др. Индуцированная амиодароном дисфункция щитовидной железы (патогенез, диагностика, лечение). Обзор. Терапевтический архив. 2003;75(8):92-96).
  16. Tanda ML, Piantanida E, Lai A et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf). 2008; 69: 812–818.
  17. Raghavan RP, Taylor PN, Bhake R et al. Amiodarone-induced thyrotoxicosis: an overview of UK management. Clin Endocrinol (Oxf). 2012; 77: 936–937.
  18. Platonova NM, Molashenko NV, Sviridenko NYu,  et al. Amiodarone- associated thyroid dysfunction. Prevalence and correction possibilities. Cardiology. 2004;10:32-38. Russian. (Платонова Н.М., Молашенко Н.В., Свириденко Н.Ю. и др. Амиодарон-ассоциированная дисфункция щитовидной железы. Частота развития и возможности коррекции. Кардиология. 2004; 10: 32-38).
  19. Zhong B, Wang Y, Zhang G, Wang Z. Environmental iodine content, female sex and age are associated with new-onset amiodarone-induced hypothyroidism: a systematic review and meta-analysis of adverse reactions of amiodarone on the thyroid. Cardiology. 2016; 134: 366–371.
  20. Rizzo  LFL, Mana DL, Serra HA. Drug-induced hypothyroidism. MEDICINA (Buenos Aires) 2017; 77: 394-404.
  21. Nademanee K, Piwonka RW, Singh BN, Hershman JM. Amiodarone and thyroid function. Progr Cardiovasc Dis. 1989;31(6):427–37.
  22. Bogazzi F, Tomisti L, Bartalena L et al. Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest. 2012; 35: 340–348.
  23. Batcher EL, Tang XC, Singh BN, et al. (SAFE-T Investigators.) Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007;120:880-885.
  24. Benjamens S, Dullaart RPF., Sluiter WJ, et al. The clinical value of regular thyroid function tests during amiodarone treatment. European J Endocrinol. 2017; 177: 9–14.
  25. Serdiuk SE, Bakalov SA, Golitsyn SP, et al. Incidence and predictors of thyroid dysfunction caused by long-term intake of amiodarone. Terapevticheskiy  Arkhiv. 2005; 77 (10): 33–39. Russian. (Сердюк С. Е., Бакалов С. А., Голицын С. П. и др. Частота возникновения и предик­торы развития амиодарон-ассоциированных дисфункций щитовидной железы. Терапевтический архив. 2005; (10): 33–39).
  26. Bartalena LA, Bogazzi FB, Chiovato LC et al. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018;7:55–66.
  27. Grineva EN, Dora SV, Malahova TV, Malahova ZL. Amiodarone impact on thyroid structure and function. Problems of endocrinology. 2008;54(3):17-21. Russian. (Гринева Е.Н., Дора С.В. Малахова Т.В., Малахова З.Л. Влияние амиодарона на струкутуру и функцию щитовидной железы. Проблемы эндокринологии. 2008; 54 (3):17-21).
  28. Connolly SJ Evidence-based analysis of amiodarone efficacy and safety. Circulation. 1999; 100: 2025-2034.
  29. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: A meta-analysis. Mayo Clin Proc. 2009; 84: 234-242.
  30. Cohen-Lehman J, Dahl P, Danzi S et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010; 6: 34-41.
  31. Elnaggar MN, Jbeili K, Nik-Hussin N et al. Amiodarone-induced thyroid dysfunction: a clinical update. Exp Clin Endocrinol Diabetes. 2018 Jun;126(6):333-341.
  32. Unger J, Lambert M, Jonckheer MH, Denayer P. Amiodarone and the thyroid: pharmaco­logical, toxic and therapeutic effects. J Intern Med 1993; 233: 435–443.
  33. Raber W. et al. Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid 2002;Vol.12(8):725-731.
  34. Tomisti L, Rossi G, Bartalena L, Martino E, Bogazzi F. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol . 2014;171:363–8.
  35. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724-734.
  36. Grebe S.K., Kahaly G.J. Laboratory testing in hyperthyroidism. Am J Med. 2012; 125(9):S2.
  37. Kahaly G.J., Olivo PD. Graves’ disease. N Engl J Med. 2017; 376(2): 184
  38. Kahaly G.J., Diana T. TSH receptor antibody functionality and nomenclature. Front Endocrinol. 2017; 8: 28
  39. Tozzoli R., Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev. 2012; 12(2):107–113
  40. Bogazzi F, Bartalena L, Dell’Unto E et al. Proportion of type 1 and type 2 amio­darone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf). 2007; 67: 533–537.
  41. Maqdasy S, Batisse-Lignier M, Auclair C et al.  Amiodarone-induced thyrotoxicosis recurrence after amiodarone reintroduction. Am J Cardiol. 2016; 117: 1112– 1116.
  42. Ulupova EO, Bogdanova GA., Karonova TL., Grineva EN. Serum free thyroid hormones ratio  in amiodarone-induced thyrotoxicosis types 1 and 2. Translational Medicine. 2018;5(3):28-35. Russian. (Улупова Е.О., Богданова Г.А., Каронова Т.Л., Гринева Е.Н. Соотношение свободных тиреоидных гормонов в сыворотке крови больных амиодарон-индуцированным тиреотоксикозом 1 и 2 типов. Трансляционная медицина. 2018; 5(3):28-35).
  43. Tomisti L., Urbani C, Rossi G et al.  The presence of anti-thyroglobulin (TgAb) and/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2 ami­odarone-induced thyrotoxicosis. J Endocri­nol Invest. 2016; 39: 585–591.
  44. Sriphrapradang C., Bhasipol A.  Differentiating Graves" disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine. Annals of Medicine and Surgery. 2016; 10: 69-72.
  45. Bartalena L, Brogioni S, Grasso L et al. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab. 1996;81:2930–3.
  46. Smith T.J., Hegedus L: Graves’ disease. N Engl J Med. 2016; 375: 1552–1565
  47. Goichot B., Bouee S, Castello-Bridoux C, Caron P: Survey of clinical practice patterns in the management of 992 hyperthyroid patients in France. Eur Thyroid J. 2017; 6(3): 152–159
  48. Kwak J.Y., Han KH, Yoon JH, Moon HJ, Son EJ, Park SH, Jung HK, Choi JS, Kim BM, Kim EK. Thyroid Imaging Reporting and Data System for US Features of Nodules: A Step in Establishing Better Stratification of Cancer Risk. Radiology. 2011;260(3):892-899
  49. Дедов ИИ, Мельниченко ГА, Свириденко НЮ, Платонова НМ. Диагностика, профилактика и лечение ятрогенных йодиндуцированных заболеваний щитовидной железы. Вестник РАМН. 2006; 2: 15–22
  50. Theodoraki A, Vanderpump MPJ. Thyrotox­icosis associated with the use of amiodarone: the utility of ultrasound in patient manage­ment. Clin Endocrinol (Oxf). 2016;84:172– 176.
  51. Loy M, Perra E, Melis A et al. Color-flow Doppler sonography in the differential diag­nosis and management of amiodarone-in­duced thyrotoxicosis. Acta Radiol. 2007; 48: 628–634.
  52. Piga M, Cocco MC, Serra A et al. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyro­toxicosis. Eur J Endocrinol. 2008; 159: 423– 429.
  53. Wong, R, Cheung, W, Stockigt, JR et al. Heterogeneity of  amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response. Internal Medicine Journal 2003;33: 420–426.
  54. Bogazzi F, Bartalena L, Brogioni S et al. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid. 1997;7: 541-545.
  55. Bogazzi F, Martino E, Dell’Unto E et al. Thyroid color flow Doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. Journal of Endocrinological Investigation. 2003;26:635-640.
  56. Eaton SEM, Euinton HA, Newman CM et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf). 2002;56:33-8.
  57. Daniels, G.H. Amiodarone-induced thyrotoxicosis. Journal of Clinical Endocrinology and Metabolism. 2001; 86: 3–8.
  58. Pattison DA, Westcott J, Lichtenstein M et al. Quantitative assessment of thy­roid-to-background ratio improves the in­terobserver reliability of technetium-99m ses­tamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nucl Med Commun. 2015; 36: 356–362.
  59. Wang J and  Zhang R. Evaluation of 99mTc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis. Br J Radiol. 2017; 90: 20160836.
  60. Censi S, Bodanza V, Manso J et al. Amiodarone-induced thyrotoxicosis differential diagnosis using 99mTc-SestaMIBI and target-to-background ratio (TBR). Clin Nucl Med. 2018;43:65-662.
  61. Oki GSR, Zantut-Wittmann DE, Guariento MH et al. Tc-99m Sestamibi thyroid imaging in patients on chronic amiodarone treatment.  Comparison with Tc-99m pertechnetate imaging. Clin Nucl Med. 2010;35: 223–227.
  62. Souto SB, Fernandes H, Matos MJ, et al. Importance of (99)mtC-sestaMIBI thyroid scan in a case of amiodarone induced thyrotoxicosis. Arquivos brasileiros de endocrinologia e metabologia. 2011;55:486-489.
  63. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009; 23: 735–751.
  64. Osman F, Franklyn JA, Sheppard MC et al Successful treatment of amiodarone-induced thyrotoxicosis. Circulation. 2002;105:1275-1277.
  65. Bogazzi F, Tomisti L, Rossi G et al. Glucocorticoids are preferable to thionamides as first- line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J Clin Endocrinol Metab. 2009;94:3757–3762.
  66. Braverman LE, He X, Pino S et al. The effect of perchlorate, thiocyanate, and nitrate on thyroid function in workers exposed to perchlorate long-term. J Clin Endocrinol Metab. 2005;90(2):700–6.
  67. Shubert L., Bricaire L., Groussin L.  Amiodarone-induced thyrotoxicosis. Ann Endocrinol (Paris).2020;Apr 29:S0003-4266(20)30066-4. Online ahead of print
  68. Martino E, Aghini-Lombardi F,  Mariotti S et al. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf). 1987 Feb;26(2):227-37. 
  69. Dickstein G, Shechner C,  Adawi F et al. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med. 1997 May; 102(5):454-8.
  70. Papi G, Corsello SM, Pontecorvi A. Clinical concepts on thyroid emergencies. Front Endocrinol (Lausanne). 2014 Jul 1;5: article 102(1-9).
  71. Campi I, Perego GB, Ravoli A, et al. Pulsed intravenous methylprednisolone combined with oral steroids as a treatment for poorly responsive type 2 amiodarone-induced thyrotoxicosis. European Journal of Endocrinology. 2019;181:519-524.
  72. Cappellani D., Urbani C., Manetti L., et al. Effect of high dose intravenous glucocorticoid therapy on serum thyroid hormone concentrations in type 2 amiodarone induced thyrotoxicosis : an exploratory study. Journal of Endocrinological Investigation. 2020;Apr 16:Published online 16 April 2020.
  73. Gough J, Gough IR. Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. World J Surg. 2006;30:1957-1961.
  74. Kaderli RM, Fahrner R, Christ ER et al. Total thyroidectomy for amiodarone-induced thyrotoxicosis in the hyperthyroid state. Exp Clin Endocrinol Diabetes. 2016;124:45–48.
  75. Hamoir E, Meurisse M, Defechereux T et al. Surgical management of  amiodarone-associated thyrotoxicosis: too risky or too effective? World J Surg. 1998; 22: 537–542.
  76. Mulligan DC, McHenry CR, Kinney W et al. Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy. Surgery. 1993;114:1114-1119.
  77. Meerwein C., Vital D., Greutmann M et al. Total thyroidectomy in patients with amiodarone-induced hyperthyroidism: when does the risk of conservative treatment exceed the risk of surgery? HNO. 2014; 62: 100–105.
  78. Cappellani D, Papini P, Pingitore A et al. Comparison between total thyroidectomy and medical therapy for amiodarone-induced thyrotoxocosis. J Clin Endocrinol Metab. 2020 Jan;105(1):242-251.
  79. Houghton SG, Farley DR, Brennan MD et al. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg. 2004;28:1083-1087.
  80. Samaras K, Marel GM. Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis. Clin Endocrinol. 1996;45:365-368.
  81. Diamond T, Rajagopal R, Ganda K. Plasmapheresis as a potential treatment option for amiodarone-induced thyrotoxicosis. Internal Medicine Jouranal. 2004;34:369-370.
  82. Zhu L, Zainudin S, Kaushik M et al. Plasma exchange in the treatment of thyroid storm secondary to type II amiodarone-induced thyrotoxicosis. Endocrinology, diabetes and metabolism. Case reports.  ID: 16-0039; July 2016 DOI: 10.1530/EDM-16-003
  83. Tonnelier A, J. de Filette, Ann De Becker et al. Successful pretreatment using plasma exchange before thyroidectomy in a patient with amiodarone-induced thyrotoxicosis. Eur Thyroid J. 2017;6:108–112.
  84. Goldschlager N, Epstein AE, Naccarelli G et al. Practical guide for clinicians who treat patients with amiodarone: 2007.  Heart Rhythm. 2007; 4: 1250-1259.
  85. Siddoway L. A. Amiodarone: Guidelines for Use and Monitoring. American family physician. 2003;68:2189-2196.
  86. Trohman R.G., Sharma P.S., McAninch E.A., Bianco A.C. Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. Trends Cardiovasc Med. 2019 July; 29(5):285-295.
  87. Philippou G, Koutras DA, Piperingos G et al. The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clin Endocrinol (Oxf). 1992; 36: 573-8.
  88. Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff Chaikoff effects is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999; 140: 3404–10.
  89. Rosene ML, Wittmann G,  Drigo RA et al. Inhibition of the Type 2 Iodothyronine Deiodinase Underlies the Elevated Plasma TSH Associated with Amiodarone Treatment. Endocrinology. 2010 Dec; 151(12): 5961–5970.
  90. Kryukov EV, Potekhin NP, Fursov AN et al. Крюков Algorithm of management of patients treated with amiodarone depending on thyroid functional state. Clinical Medicine. 2017; 95(10):901-904. Russian. Крюков ЕВ, Потехин НП, Фурсов АН и др. Алгоритм ведения пациентов, получающих амиодарон, в зависимости от функционального состояния щитовидной железы. Клиническая медицина. 2017;95(10):901-904.
  91. Young R., Worthley L. I. G. Diagnosis and management of thyroid disease and the critically ill patient //Critical Care and Resuscitation. – 2004. – Т. 6. – №. 4. – С. 295-305.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*